India, Oct. 1 -- Regeneron Pharmaceuticals, Inc. (REGN), a biopharmaceutical company, reported new clinical data for ubamatamab in advanced low-grade serous ovarian cancer (LGSOC) and trevogrumab in people with obesity receiving semaglutide.
The data were presented at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting and the European Association for the Study of Diabetes (EASD) Annual Meeting, respectively.
Regeneron develops medicines across oncology, obesity and other areas, with ubamatamab and trevogrumab among its investigational clinical programs.
Ubamatamab In Ovarian Cancer
Ubamatamab is an investigational MUC16xCD3 bispecific antibody designed to bridge MUC16 on cancer cells with CD3-expressing T cel...